Two healthcare heavyweights are combining forces to form a technology center they hope will, over the next 10 years, “fundamentally advance the pace” of discovery in medical science and healthcare innovation.
In healthcare, it is likely that an increased demand for telehealth will remain, meaning providers will need to continue ramping up their capabilities and personalizing this care.
A new wave of COVID-19 cases has the new director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, “scared,” she said during a March 29 White House briefing.
Last week a literature review showed none of 62 high-quality medical AI models ready for translation from academic research to clinical practice. Now comes a similar but separate study confirming the depth of the dashed hopes.
Noting that multiple sclerosis now affects more people between 50 and 60 than any other age group, researchers have shown how machine-learning gait analysis can help personalize therapy regimens.
Academic researchers in the U.K. have completed a systematic review of 62 representative studies on the use of AI for COVID-19 diagnostics and prognostics on X-rays and CT scans. Their findings may strike some as a setback.
Of five emerging technologies used by nurses to help control infectious diseases, the Internet of Things is the most promising, researchers have concluded.
The demand for tailored PHI consent for research is strongest among adults 49 and younger, pressing the need to speed the evolution of policies conducive to AI development.
The FDA has granted 510(k) clearance to clinical decision support software that uses AI to detect small but potentially cancerous lesions in the lungs.
